Browsing by Author "Soyer, Nur"
Now showing 1 - 3 of 3
- Results Per Page
- Sort Options
Publication Efficacy and safety of ruxolitinib in patients with myelofibrosis: A retrospective and multicenter experience in Turkey(Tubitak Scientific & Technological Research Council Turkey, 2021-01-01) Soyer, Nur; Ali, Ridvan; Turgut, Mehmet; Haznedaroglu, Ibrahim C.; Yilmaz, Fergun; Aydogdu, Ismet; Karakus, Volkan; Ozgur, Gokhan; Kis, Cem; Ceran, Funda; Ilhan, Gul; Ozkan, Melda; Aslaner, Muzeyyen; Ince, Idris; Yavasoglu, Irfan; Gediz, Fusun; Sonmez, Mehmet; Guvenc, Birol; Ozet, Gulsum; Kaya, Emin; Vural, Filiz; Tobu, Mahmut; Durusoy, Raika; Pir, Ali; KAYA, PİR ALİ; Vural, Filiz; Şahin, Fahri; Saydam, Guray; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Hematoloji Anabilim Dalı.; 0000-0001-5118-6894; 0000-0001-9178-2850; 0000-0001-7423-7180; 0000-0002-7798-4349; 0000-0001-6621-3138; 0000-0002-2176-4371; 0000-0001-8605-8497; 0000-0003-1041-8462; W-3827-2017; ABH-5764-2020; AAB-7711-2022; JYO-9281-2024; W-2951-2017; HRC-6282-2023; W-7916-2019; B-7408-2009; A-4238-2018Background/aim: The aim of this study is to assess the efficacy and safety of ruxolitinib in patients with myelofibrosis. Materials and methods: From 15 centers, 176 patients (53.4% male, 46.6% female) were retrospectively evaluated. Results: The median age at ruxolitinib initiation was 62 (28-87) and 100 (56.8%) of all were diagnosed as PMF. Constitutional symptoms were observed in 84.7%. The median initiation dose of ruxolitinib was 30 mg (10-40). Dose change was made in 69 (39.2%) patients. Forty seven (35.6%) and 20 (15.2%) of 132 patients had hematological and nonhematological adverse events, respectively. The mean spleen sizes before and after ruxolitinib treatment were 219.67 +/- 46.79 mm versus 199.49 +/- 40.95 mm, respectively (p < 0.001). There was no correlation between baseline features and subsequent spleen response. Overall survival at 1-year was 89.5% and the median follow up was 10 (1-55) months. We could not show any relationship between survival and reduction in spleen size (p = 0.73). Conclusion: We found ruxolitinib to be safe, well tolerated, and effective in real-life clinical practice in Turkey. Ruxolitinib dose titration can provide better responses in terms of not only clinical benefit but also for long term of ruxolitinib treatment.Publication Patterns of hydroxyurea prescription and use in routine clinical management of polycythemia vera: A multicenter chart review study(Galenos Yayincilik, 2020-01-01) Büyükaşık, Yahya; Turgut, Mehmet; Saydam, Güray; Yavuz, Selim; Ünal, Ali; Ar, Muhlis Cem; Ayyıldız, Orhan; Altuntaş, Fevzi; Okay, Mufide; Çiftçiler, Rafiye; Meletli, Özgür; Soyer, Nur; Mastanzade, Metban; Güven, Zeynep; Soysal, Teoman; Karakuş, Abdullah; Yiğenoğlu, Tuğce Nur; Uçar, Barış; Gökçen, Ece; Tuğlular, Tülin; Ali, Rıdvan; ALİ, RIDVAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Hematoloji Anabilim Dalı.; GXD-8209-2022Objective: This study aimed to evaluate real-life data on patterns of hydroxyurea prescription/use in polycythemia vera (PV).Materials and Methods: This retrospective chart review study included PV patients who had received hydroxyurea therapy for at least 2 months after PV diagnosis. Data were collected from 10 representative academic medical centers.Results: Of 657 patients, 50.9% were in the high-risk group (age 60 years and/or history of thromboembolic event). The median duration of hydroxyurea therapy was 43.40 months for all patients; 70.2% of the patients had ongoing hydroxyurea therapy at last followup. Hydroxyurea was discontinued in 22.4% of the patients; the most common reason was death (38.5%). The predicted time until hydroxyurea discontinuation was 187.8 months (standard error: +/- 21.7) for all patients. This duration was shorter in females (140.3 +/- 37.7 vs. 187.8 +/- 29.7) (p=0.08). This trend was also observed in surviving patients aged >= 50 years at hydroxyurea initiation (122.2 +/- 12.4 vs. 187.8 +/- 30.7, p=0.03). Among the patients who were still on hydroxyurea therapy, 40.3% had a hematocrit concentration of >= 45% at their last followup visit, and the rate of patients with at least one elevated blood cell count was 67.8%.Conclusion: Hydroxyurea prescription patterns and treatment aims are frequently not in accordance with the guideline recommendations. Its discontinuation rate is higher in females.Item Retrospective and multicenter analysis of efficacy and safety of ruxolitinib in 176 Turkish patients with myelofibrosis: updated data(Pergamo-Elsevier Sciens Ltd, 2018-10) Soyer, Nur; Turgut, Mehmet; Haznedaroğlu, İbrahim; Yılmaz, Fergün; Aydoğdu, İsmet; Pir, Ali; Karakuş, Volkan; Özgür, Gökhan; Kis, C.; Ceran, Funda; İlhan, Gül; Özkan, Melda; Arslaner, M.; İnce, İdris; Ali, Rıdvan; Uludağ Üniversitesi/Tıp Fakültesi/Dahiliye Bilim Dalı.